A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

Brief description of study

From sponsor: As background, this protocol started as a Phase I Dose Escalation and is now a Phase I/II Escalation/Expansion. This protocol has increased in complexity in each version and protocol version 6.0 is now a more streamlined protocol version with focus on Dose Expansion. To note: • All groups are closed. Phase 1 is completed. • Phase II Group B -enrolled 3 patients (HB-201 + pembrolizumab); closed to recruitment • Focus is Phase II Groups E&F o HB-200 two-vector therapy + pembrolizumab


Clinical Study Identifier: s21-00729
ClinicalTrials.gov Identifier: NCT04180215
Principal Investigator: Zujun Li.
Other Investigators: Elise M Zahriah, Colin Hill, Michael Persky, Danny Perlaza, Catherine M Concert, Marissa Rybstein, Tuyet-Phuong N Tran, Adam S Jacobson, Ann M Riccobene, Caitlin Elizabeth Ryan, Megan DiBenedetto, Kenneth S Hu.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.